96835-27-7

Basic information

• Product Name: 4-Pyridinemethanol, a-(4-fluorophenyl)-a-phenyl-
• CAS NO: 96835-27-7
• Molecular Formula: C18H14FNO
• Molecular Weight: 279.314
• Mol File: 96835-27-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-Pyridinemethanol, a-(4-fluorophenyl)-a-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridinemethanol, a-(4-fluorophenyl)-a-phenyl-(96835-27-7)
• EPA Substance Registry System: 4-Pyridinemethanol, a-(4-fluorophenyl)-a-phenyl-(96835-27-7)

Safety Data

• Hazardous Substances Data: 96835-27-7(Hazardous Substances Data)

Upstream product

• 14548-46-0 4-Benzoylpyridine 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 352-13-6 4-flourophenylmagnesium bromide 

Downstream Products

• 96835-33-5 1-Ethyl-4-[(4-fluoro-phenyl)-hydroxy-phenyl-methyl]-pyridinium; iodide 
• 96835-39-1 4-[(4-Fluoro-phenyl)-phenyl-methylene]-1-methyl-piperidine 
• 96835-40-4 1-Ethyl-4-[(4-fluoro-phenyl)-phenyl-methylene]-piperidine 
• 96835-37-9 (1-Ethyl-piperidin-4-yl)-(4-fluoro-phenyl)-phenyl-methanol 
• 96835-06-2 (4-Fluoro-phenyl)-(1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl)-phenyl-methanol 
• 96835-11-9 4-[(4-Fluoro-phenyl)-phenyl-pyridin-4-yl-methyl]-morpholine 
• 96835-48-2 4-[1-(4-Fluoro-phenyl)-1-phenyl-meth-(Z)-ylidene]-1-methyl-piperidin-3-ol 
• 93075-98-0 (4-Fluoro-phenyl)-(1-methyl-piperidin-4-yl)-phenyl-methanol 
• 111626-75-6 1-[4-(3-{4-[(4-Fluoro-phenyl)-phenyl-methyl]-piperidin-1-yl}-propoxy)-3-methoxy-phenyl]-ethanone 
• 111627-67-9 4-[(4-fluorophenyl)phenylmethyl]piperidine 
• 785734-48-7 4-[Chloro-(4-fluoro-phenyl)-phenyl-methyl]-pyridine 
• 135256-94-9 4-[(4-Fluoro-phenyl)-phenyl-methyl]-pyridine 
• 96835-32-4 4-[(4-Fluoro-phenyl)-hydroxy-phenyl-methyl]-1-methyl-pyridinium; iodide 

Relevant articles and documents

Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents

A method of treating cardiac dysfunction, the effects of histamine, and gastric secretion excesses with aryl(alkyl and alkylene)-N-[(phenoxy and phenythio)alkyl]aminoheterocyclics corresponding to the formula: STR1 wherein Ar is phenyl or substituted phenyl; R is phenyl, substituted phenyl, pyridinyl or cycloalkyl; A is hydrogen, hydroxy, cyano, amido and amino; Q is --CH2 --, --CH--, or --CHOH--; d and n are zero or one and the dotted lines form double bonds consistent with the valence of carbon; p is zero, one or two; m is one to six inclusive; B is oxygen, nitrogen, sulfur, sulfinyl or sulfonyl; z is zero or one; l is zero or one; W is hydrogen, loweralkyl, halo, nitro, loweralkoxy or hydroxy; X is hydrogen, loweralkyl, halogen, loweralkoxy or hydroxy; Y is --CH(OH)CH2 OH, --CH(OH)C(O)OH, --C(O)C(O)OH, --C(O)CH2 OH,--C(O)C(O)OCH3, --C(O)C(O)OC2 H5, --CH2 C(O)OC2 H5, --CH(OH)C(O)OCH3, --CH(OH)C(O)OC2 H5 or --C(O)CH2 OC(O)CH3 ; and the pharmaceutically acceptable salts thereof; in addition to the above methods of treatment, compounds wherein (B)z is oxygen are useful in a method of treating Gell and Coombs type 1 allergic responses in mammals.

Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment

A method of inhibiting Type 1 allergic responses in a living animal body with substituted heterocyclic amines is disclosed wherein the active agents are expressed generally by the formula which includes certain known and certain known compounds: STR1 wherein P is zero, one or two; m is one to six inclusive; A is selected from hydrogen, hydroxy or cyano; d is zero or one; Q is --CH--, CH2 -- or STR2 n is zero or one and when Q is --CH-- and n is one, a double bond is formed with one of the adjacent carbons but not both at the same time, and when n and d are zero at the same time, a double bond is formed between the α carbon and a carbon of the central heterocyclic amine ring; Ar, D and R are selected from phenyl, substituted phenyl, pyridinyl, thienyl, furanyl or naphthyl and in addition, R may have the values benzyl, substituted benzyl, cycloalkyl or loweralkyl and D may additionally have the values: 2H-1-benzopyran-2-one,4-oxo-4H-1-benzopyran-2-carboxylic acid loweralkyl ester, 2,3-dihydro-4H-1-benzopyran-4-one, 1,4-benzodioxanloweralkyl-2-yl or 1,1'-biphenyl-4-yl and the pharmaceutically acceptable salts thereof.